ArticleOpen medicine (Warsaw, Poland)2026
Association between triglyceride-glucose index and sarcopenia in older adults without either dysglycemia or central obesity: a cross-sectional study from CHARLS.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study investigated the association between the triglyceride-glucose (TyG) index and sarcopenia in a metabolically healthier older population. Methods: This cross-sectional study utilized data from China Health and Retirement Longitudinal Study (CHARLS), involving 1,544 participants aged ≥60 years who were free of both dysglycemia (i.e., diabetes or prediabetes) and central obesity. Logistic regression was used to evaluate the association between the TyG index and sarcopenia. Results: Participants with sarcopenia had a significantly lower TyG index than those without sarcopenia (8.29 [8.01-8.59] vs. 8.38 [8.07-8.69]; p=0.001), and the prevalence of sarcopenia declined progressively across TyG quartiles (Q1-Q4: 54.3 %, 53.4 %, 47.4 %, 43.8 %; p for trend=0.001). After adjustment for significant covariates, a higher TyG index was independently associated with lower odds of sarcopenia (per quartile: OR = 0.826, 95 % CI: 0.720-0.947; per unit: OR = 0.714, 95 % CI: 0.517-0.985). Compared with the lowest quartile, participants in the highest quartile had a 44.8 % lower odds of sarcopenia (OR = 0.552, 95 % CI: 0.357-0.852). Conclusion: Among older adults without either dysglycemia or central obesity, a higher TyG index was independently associated with a lower odds of sarcopenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.